Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MBRX
MBRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MBRX News
Moleculin Biotech Advances Cardiac Safety Profile in Annamycin Trials
2d ago
Newsfilter
Moleculin Biotech Presents Annamycin Cardiac Safety Data at ASCO Annual Meeting
May 21 2026
Newsfilter
Moleculin Biotech Reports Q1 Earnings Miss
May 15 2026
seekingalpha
Moleculin Biotech Reports Early Results from MIRACLE Trial Indicating 40% Remission Rate
May 15 2026
Newsfilter
Moleculin Biotech Reveals Cardiac Safety Data for Annamycin
May 12 2026
Newsfilter
Moleculin Biotech's Drug Data Accepted for ASCO Presentation
Apr 21 2026
Newsfilter
Moleculin Biotech Highlights Annamycin's Safety Profile in CEO Corner
Apr 07 2026
Newsfilter
Moleculin Biotech Files to Sell 6.37M Shares
Mar 30 2026
seekingalpha
Avaí Bio Initiates α-Klotho Cell Production Phase
Mar 27 2026
PRnewswire
Global Cell Therapy Market Reaches Inflection Point with $7 Billion Projection
Mar 27 2026
Newsfilter
Moleculin Biotech Reports FY EPS of -$28.42
Mar 19 2026
seekingalpha
U.S. Stocks Close Lower, Dow Jones Falls Over 300 Points
Feb 19 2026
Benzinga
U.S. Stocks Open Lower with Dow Down Over 250 Points
Feb 19 2026
Benzinga
Moleculin Biotech Exercises Warrants for $8.3M
Feb 19 2026
seekingalpha
Moleculin Biotech Reports Significant Progress
Feb 18 2026
stocktwits
Moleculin Biotech Reports Progress in Annamycin Clinical Trial
Feb 18 2026
Newsfilter
Show More News
